Schmittdiel Julie, Vijan Sandeep, Fireman Bruce, Lafata Jennifer Elston, Oestreicher Nina, Selby Joe V
Kaiser Permanente Northern California Division of Research, Oakland, California 94612, USA.
Med Care. 2007 Apr;45(4):315-21. doi: 10.1097/01.mlr.0000254582.85666.01.
Control of blood pressure, low-density lipoprotein cholesterol (LDL-c), and A1c can lower the risk for diabetes complications. These quality indicators often are examined separately and weighted equally in performance measurement, potentially discarding important information.
We sought to create a composite indicator of the clinical benefit, or value, of diabetes risk factor control that appropriately weights the clinical importance of A1c, LDL-c, and blood pressure, and to test its usability for quality measurement.
The combined value of control for 3 diabetes risk factors, measured by predicted quality-adjusted life years (QALYs), was compared in diabetes patients (n = 129,236 in 2001; n = 185,006 in 2003) in Kaiser Permanente Northern California across 16 medical center populations in 2001 and 2003 using hierarchical linear regression to adjust for case-mix differences. Patient-level QALYs, simulated from risk factor and case-mix variables in a Markov model, was the main outcome variable.
There was significant cross-sectional variability in average case-mix adjusted QALYs for diabetes patients across centers in 2003. QALYs increased from 2001 to 2003 as the result of improved risk factor control; longitudinal improvements in QALYs also showed variation across centers. Regression analyses demonstrated the greater impact of blood pressure versus LDL-c or A1c control on QALYs, and the greater value of risk factor control in those with poor versus near or in-control blood pressure.
Using predicted QALYs to measure value holds promise as a sensitive composite indicator for quality measurement. Complex, evidence-based quality indicators such as these can potentially provide accurate and useful information to health plans, providers, and consumers.
控制血压、低密度脂蛋白胆固醇(LDL-c)和糖化血红蛋白(A1c)可降低糖尿病并发症风险。这些质量指标在绩效评估中通常被分别检查且权重相同,这可能会丢弃重要信息。
我们试图创建一个糖尿病危险因素控制的临床益处或价值的综合指标,该指标能适当权衡A1c、LDL-c和血压的临床重要性,并测试其在质量测量中的可用性。
通过预测的质量调整生命年(QALYs)来衡量3个糖尿病危险因素的综合控制价值,并在2001年和2003年对北加利福尼亚州凯撒医疗集团16个医疗中心人群中的糖尿病患者(2001年n = 129,236;2003年n = 185,006)进行比较,使用分层线性回归来调整病例组合差异。从马尔可夫模型中的危险因素和病例组合变量模拟得出的患者水平QALYs是主要结局变量。
2003年各中心糖尿病患者的平均病例组合调整后QALYs存在显著的横断面差异。由于危险因素控制的改善,QALYs从2001年到2003年有所增加;各中心QALYs的纵向改善也存在差异。回归分析表明,血压控制对QALYs的影响大于LDL-c或A1c控制,且在血压控制不佳与接近或控制良好的患者中,危险因素控制的价值更大。
使用预测的QALYs来衡量价值有望成为一种敏感的质量测量综合指标。像这样基于证据的复杂质量指标可能会为健康计划、医疗服务提供者和消费者提供准确且有用的信息。